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Abstract: Cancer remains one of the leading causes of mortality worldwide and the associated
reduction in physical function has a marked impact on both quality of life and survival. The aim of
the present study was to examine the relationship between Eastern Cooperative Oncology Group-
Performance status (ECOG-PS), modified Glasgow Prognostic Score (mGPS), Body Mass Index/
Weight Loss grade (BMI/WL grade), and Computerised Tomography (CT)-derived body composition
measurement and physical function in patients with advanced cancer. Nine sites contributed
prospective data on patient demographics, ECOG-PS, mGPS, physical function tests, and CT-derived
body composition. Categorical variables were analysed using χ2 test for linear-by-linear association,
or χ2 test for 2-by-2 tables. Associations were analysed using binary logistic regression. A total
of 523 cancer patients (266 males, 257 females) were included in the final analysis and most had
metastatic disease (83.2%). The median overall survival was 5.6 months. On multivariate binary
logistic regression analysis, a high ECOG-PS remained independently associated with a low skeletal
muscle index (p < 0.001), low skeletal muscle density (p < 0.05), and timed up and go test failure
(p < 0.001). A high mGPS remained independently associated with a low skeletal muscle density
(p < 0.05) and hand grip strength test failure (p< 0.01). A high BMI/WL grade remained independently
associated with a low subcutaneous fat index (p < 0.05), low visceral obesity (p < 0.01), and low
skeletal muscle density (p < 0.05). In conclusion, a high ECOG-PS and a high mGPS as outlined in the
ECOG-PS/mGPS framework were consistently associated with poorer body composition and physical
function in patients with advanced cancer.
Keywords: advanced cancer; systemic inflammation; Glasgow prognostic score; body composition;
ECOG; physical function testing; computed tomography
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1. Introduction
Cancer remains one of the leading causes of mortality worldwide and is responsible for 8.8 million
deaths each year. In westernised countries, it has been estimated that one in three people will develop
cancer in their lifetime and one in four will die from it [1,2].
The importance of cachexia syndrome, with escalating nutritional and functional decline leading
to poor clinical outcomes, is well recognised [3]. However, how this complex syndrome is best
defined is the subject of continuing debate. Clearly, defining any syndrome is difficult due to its
multifaceted nature. However, in such circumstances one may resort to the duck test approach: “If it
looks like a duck, swims like a duck, quacks like a duck, then it probably is a duck”. Such abductive
reasoning has been commonly used to settle legal cases and more recently has gained popularity in
artificial intelligence.
In the context of cancer cachexia, a number of factors have been shown to impact independently
on quality of life (including functional and symptom scores) and survival. These include Eastern
Cooperative Oncology Group-Performance status (ECOG-PS) and the systemic inflammatory response
(modified Glasgow Prognostic Score, mGPS), both of which have been extensively validated [4–7].
More recently, based on an international consensus, body mass index/weight loss (BMI/WL) grades
have been shown to impact independently on quality of life and survival [8–10].
Recently, these three criteria for the definition of cancer cachexia were directly compared and all
three independently predicted survival in patients with advanced cancer [11]. However, BMI/WL
grade was low risk in approximately 50% of patients and ECOG-PS and mGPS were independently
associated with survival in this group. Therefore, to further investigate the clinical utility of these
three criteria to define cachexia, the aim of the present study was to examine the relationship between
ECOG-PS, mGPS, BMI/WL grade, and Computerised Tomography (CT)-derived body composition
and physical function tests in patients with advanced cancer.
2. Patients and Methods
2.1. Patients
A biobank of data from patients with advanced cancer was analysed. All data were collected
prospectively across 9 sites in the UK and Ireland (cancer centres, hospitals, and specialist palliative care
units) over a five-year period (2011–2016) [9,11,12]. Eligible patients provided written informed consent,
were adults, had advanced cancer including all cancer subtypes (defined as metastatic cancer with
histological, cytological or radiological evidence, that was locally advanced, or receiving anti-cancer
therapy with palliative intent) and had the ability to comply with study procedures including provision
of a venous blood sample (taken on the day of consent). Patients were either inpatients or outpatients,
undergoing anti-cancer therapy with a palliative intent including best supportive care. The study
had ethical approval in both the UK and Ireland (West of Scotland Ethics Committee UK: 18/WS/0001
(18/01/2018) and Cork Research Ethics Committee Ireland: ECM 4 (g) (03/03/2015)) and was conducted
in accordance with the Declaration of Helsinki. Furthermore, the study conformed to the STROBE
guidelines for cohort studies [13].
2.1.1. Prognostic Markers
Patient’s age, sex, and clinicopathological characteristics were recorded within 3 months prior
to study entry. Prognostic tools/factors validated in a recent systematic review by Simmons and
co-workers were used in the analysis [14].
Patients were categorized according to their ECOG-PS into five district grades (grade 0–4) as
previously described [15]. The mGPS was constructed as previously described (CRP ≤ 10 mg/L = 0,
CRP > 10 mg/L & albumin ≥ 35 g/L = 1, CRP > 10 mg/L and albumin < 35 g/L = 2) [16,17].
An autoanalyzer was used to measure serum CRP (mg/L) and albumin (g/L) concentrations (Architect;
Cancers 2020, 12, 1187 3 of 14
Abbot Diagnostics, Maidenhead, UK). Patients were categorized according to the BMI-adjusted weight
loss grade into one of five distinct weight loss grades (grades 0–4) as previously described [8,9].
2.1.2. Body Composition
CT images were obtained at the level of the third lumbar vertebra [18]. Patients whose scans
were taken ≥ 3 months prior to study entry, who had significant movement artefact, or who were
missing the region of interest were excluded. CT images were analysed using NIH Image J version 1.47
(U.S. National Institutes of Health, Bethesda, USA) or OsiriX software version 4.1.1 (OsiriX, Geneva,
Switzerland). Both imaging software packages have been shown to provide excellent agreement
for body composition measures [19]. Region of interest (ROI) measurements were made of visceral
fat areas, subcutaneous fat areas (Table 1), and skeletal muscle areas (cm2) (Table 1) using standard
Hounsfield Unit (HU) ranges (adipose tissue -190 to -30, and skeletal muscle -29 to +150). These were
then normalised for height2 to create indices: total fat index (cm2/m2), subcutaneous fat index (cm2/m2),
visceral fat index (cm2/m2), and skeletal muscle index (cm2/m2). Skeletal muscle radiodensity (HU)
was measured from the same ROI used to calculate skeletal muscle index, as its mean HU.
Table 1. CT-derived body composition measures and thresholds used.
Body Composition Measurement
High subcutaneous fat index [20]:
Subcutaneous fat area: Males >50.0 cm2m2 and Females >42.0 cm2m2
Visceral obesity [21,22]:
Visceral fat area: Males >160 cm2 and Females >80 cm2
Sarcopenia
Low skeletal muscle index [22]:
Males: BMI <25 kg/m2 and skeletal muscle index <43 cm2m2 or BMI >25 kg/m2
and skeletal muscle index <53 cm2m2
Females: BMI <25 kg/m2 and skeletal muscle index <41 cm2m2 or BMI >25 kg/m2
and skeletal muscle index <41 cm2m2
Myosteatosis
Low skeletal muscle radiodensity [22]:
BMI <25 kg/m2 and skeletal muscle radiodensity <41 HU or BMI >25 kg/m2 and
skeletal muscle radiodensity <33 HU
Visceral obesity was defined by Doyle and colleagues as a visceral fat area >160cm2 for male
patients and >80cm2 for female patients [23]. High subcutaneous fat was defined by Ebadi and
colleagues as a subcutaneous fat index ≥ 50.0 cm2m2 in males and ≥42.0 cm2m2 in females [20].
Low skeletal muscle index was defined as described by Martin and colleagues, with a skeletal muscle
index <43 cm2/m2 if BMI <25 kg/m2 and skeletal muscle index <53 cm2/m2 if BMI ≥25 kg/m2 in male
patients and skeletal muscle index <41cm2/m2 in female patients [22]. Low skeletal muscle radiodensity
was defined by Martin and colleagues as an skeletal muscle radiodensity <41HU in patients with BMI
<25 kg/m2 and <33HU in patients with BMI ≥25 kg/m2 (Table 1) [22].
Two individuals performed scan measurements (Dolan and Daly). In order to assess accuracy,
inter-rater reliability was measured in a test cohort of 20 patient images. Inter-class correlation
coefficients were 0.986 for skeletal muscle area and 0.964 for skeletal muscle radiodensity. Investigators
were blind to patient’s demographic and clinico-pathological status.
2.1.3. Physical Function
Eastern Cooperative Performance Status (ECOG-PS), timed up and go, two-minute walk, and hand
grip strength tests, as well as the presence of metastases and weight loss over the preceding three
months to study entry, were assessed by either the treating clinician or clinical research staff. Timed up
and go test and two-minute walk test completion were recorded contemporaneously with completion
being recorded as a test pass. A failure of timed up and go has previously been defined by Kear
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and co-workers for patients under 60 and by Rockwood and co-workers in patients over 60 [24–26].
A failure of the two-minute walk test has previously been defined by Bohannon and co-workers for
male and female patients between 18 and 85 years of age [27]. A weak hand grip strength test was
defined by Studenski and co-workers as <26 kg in men and <16 kg in women [28]. Patients who
achieved a hand grip strength results below the above thresholds were deemed to have failed the hand
grip strength test.
2.2. Statistical Analysis
Body composition measurements were presented as median and range and compared using
Mann–Whitney or Kruskal–Wallis tests. Categorical variables were analysed using χ2 test for
linear-by-linear association, or χ2 test for 2-by-2 tables.
Associations between ECOG-PS, mGPS, BMI-WL grades, body composition, physical function
tests, and survival were analysed using univariate and a multivariate backward conditional approach.
A p < 0.05 was applied to inclusion at each step in the multivariate analysis.
Missing data were excluded from analysis on a variable by variable basis. Two-tailed p values
<0.05 were considered statistically significant. Statistical analysis was performed using SPSS software
version 21.0. (SPSS Inc., Chicago, IL, USA).
3. Results
A total of 523 patients (266 males, 257 females) satisfied the inclusion criteria. The relationship
between clinicopathological characteristics, body composition, and physical function is shown in
Table 2. The majority of patients were over 65 (56.8%), had a BMI >25 kg/m2 (50.1%), and had
metastasis (83.2%). Gastrointestinal (34.4%) and lung (31.7%) cancers were the most common tumours.
The median overall survival was 5.6 months (95% CI: 5.1–6.0 months). At the date of censoring,
318 patients (61%) were dead. Median follow-up time for patients that had died was 10.5 months
(95% CI: 9.0–12.1 months).
Table 2. Clinicopathological characteristics of patients who met the inclusion criteria (n = 523).
Characteristic n = 523 (%)
Clinico-pathological
Age <65 226 (43.2)
65–74 165 (31.5)
>74 132 (22.5)
Sex Male 266 (50.9)
Female 257 (49.1)
Cancer Location Lung 177 (33.8)
Gastrointestinal 180 (34.4)
Other 166 (31.7)
Metastatic Disease No 88 (16.8)
Yes 435 (83.2)
Previous Anti-Cancer Therapy
Chemotherapy No 149 (28.5)
Yes 374 (71.5)
Radiotherapy No 362 (69.2)
Yes 161 (30.8)
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Table 2. Cont.
Characteristic n = 523 (%)
Hormones No 470 (89.9)
Yes 53 (10.1)
Performance status
ECOG-PS
Low Risk 0/1 255 (48.8)
Intermediate Risk 2 204 (39.0)
High Risk 3/4 64 (12.2)
Timed up and go test
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ECOG-PS   
Low Risk 0/1 255 (48.8) 
Intermediate Risk 2 204 (39.0) 
High Risk 3/4 64 (12.2) 
Timed up and go test ˥ Pass 125 (30.9) 
 Fail 279 (69.1) 
Two-minute walk test ˦ Pass 10 (2.5) 
 Fail 393 (97.5) 
Hand grip strength test ˧ Pass  74 (62.2) 
 Fail 45 (37.8) 
 Systemic Inflammation  
mGPS   
Low Risk 0 217 (41.5) 
Intermediate Risk 1 91 (17.4) 
High Risk 2 215 (41.1) 
 Body composition  
BMI ≤20.0 kg/m2 74 (14.1) 
 20–21.9 kg/m2 70 (13.4) 
 22–24.9 kg/m2 117 (22.4) 
 25–27.9 kg/m2 107 (20.5) 
 ≥28.0 kg/m2 155 (29.6) 
% Weight Loss <2.5 292 (56.0) 
 ≥2.5 231 (44.0) 
BMI/WL grade   
Low Risk 0/1 276 (52.8) 
Intermediate Risk 2/3 178 (34.0) 
High Risk 4 69 (13.2) 
Subcutaneous fat index Low 54 (28.1) 
 High 138 (71.9) 
Visceral obesity Low 79 (41.1) 
 High 113 (58.9) 
Low skeletal muscle index ˩ No 162 (53.3) 
 Yes 142 (46.7) 
Low skeletal muscle radiodensity ˪ No 116 (39.7) 
 Yes 176 (60.3) 
˥ : 404, ˦ : 403, ˧ : 119, ˨ : 192, ˩ :304, ˪ : 292. 
The relationship between ECOG-PS and measures of body composition and physical function 
are shown in Table 3. ECOG-PS was significantly associated with skeletal muscle index (p < 0.05), 
skeletal muscle radiodensity (p < 0.001) and timed up and go (p < 0.001). 
Table 3. The relationship between Eastern Cooperative Oncology Group-Performance status (ECOG-
PS) and measures of body composition and physical function in patients with advanced cancer (n = 
523). 
High subcutaneous fat index n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p 
No 28 (30.8) 19 (24.7) 7 (29.2) 54 (28.1) 0.677 
Yes 63 (69.2) 58 (75.3) 17 (70.8) 138 (71.9)  
All 91 77 24 192  
High visceral obesity n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p 
No 38 (41.8) 33 (42.9) 8 (33.3) 79 (41.1) 0.700 
Yes 53 (58.2) 44 (57.1) 16 (66.7) 113 (58.9)  
All 91 77 24 192  
Pass 125 (30.9)
Fail 279 (69.1)
Two-minute walk test
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Hand grip strength test ˧ Pass  74 (62.2) 
 Fail 45 (37.8) 
 Systemic Inflammation  
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Low Risk 0 217 (41.5) 
Intermediate Risk 1 91 (17.4) 
High Risk 2 215 (41.1) 
 Body composition  
BMI ≤20.0 kg/m2 74 (14.1) 
 20–21.9 kg/m2 70 (13.4) 
 22–24.9 kg/m2 117 (22.4) 
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 High 138 (71.9) 
Visceral obesity Low 79 (41.1) 
 High 113 (58.9) 
Low skeletal muscle index ˩ No 162 (53.3) 
 Yes 142 (46.7) 
Low skeletal muscle radiodensity ˪ No 116 (39.7) 
 Yes 176 (60.3)
˥ : 404, ˦ : 403, ˧ : 119, ˨ : 192, ˩ :304, ˪ : 292. 
The relationship between ECOG-PS and measures of body composition and physical function 
are shown in Table 3. ECOG-PS was significantly associated with skeletal muscle index (p < 0.05), 
skeletal muscle radiodensity (p < 0.001) and timed up and go (p < 0.001). 
Table 3. The relationship between Eastern Cooperative Oncology Group-Performance status (ECOG-
PS) and measures of body composition and physical function in patients with advanced cancer (n = 
523). 
High subcutaneous fat index n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p 
No 28 (30.8) 19 (24.7) 7 (29.2) 54 (28.1) 0.677 
Yes 63 (69.2) 58 (75.3) 17 (70.8) 138 (71.9)  
All 91 77 24 192  
High visceral obesity n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p 
No 38 (41.8) 33 (42.9) 8 (33.3) 79 (41.1) 0.700 
Yes 53 (58.2) 44 (57.1) 16 (66.7) 113 (58.9)  
All 91 77 24 192  
Pass 10 (2.5)
Fail 393 (97.5)
Hand grip strength test
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Low skeletal muscle index ˩ No 162 (53.3) 
 Yes 142 (46.7) 
Low skeletal muscle radiodensity ˪ No 116 (39.7) 
 Yes 176 (60.3)
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The relationship between ECOG-PS and measures of body composition and physical function 
are shown in Table 3. ECOG-PS was significantly associated with skeletal muscle index (p < 0.05), 
skeletal muscle radiodensity (p < 0.001) and timed up and go (p < 0.001). 
Table 3. The relationship between Eastern Cooperative Oncology Group-Performance status (ECOG-
PS) and measures of body composition and physical function in patients with advanced cancer (n = 
523). 
High subcutaneous fat index n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p 
No 28 (30.8) 19 (24.7) 7 (29.2) 54 (28.1) 0.677 
Yes 63 (69.2) 58 (75.3) 17 (70.8) 138 (71.9)  
All 91 77 24 192  
High visceral obesity n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p 
No 38 (41.8) 33 (42.9) 8 (33.3) 79 (41.1) 0.700 
Yes 53 (58.2) 44 (57.1) 16 (66.7) 113 (58.9)  
All 91 77 24 192  
Pass 74 (62.2)
Fail 45 (37.8)
Systemic Inflamm tion
mGPS
Low Risk 0 217 (41.5)
Intermediate Risk 1 91 (17.4)
High Risk 2 215 (41.1)
Body composition
BMI ≤20.0 kg/m2 74 (14.1)
20–21.9 kg/m2 70 (13.4)
22–24.9 kg/m2 117 (22.4)
5–27.9 kg/m2 107 (20.5)
≥28.0 kg/m2 155 (29.6)
% Weight Loss <2.5 292 (56.0)
≥2.5 231 (44.0)
BMI/WL grade
Low Risk 0/1 276 (52.8)
Intermediate Risk 2/3 178 (34.0)
High Risk 4 69 (13.2)
Subcutaneous fat index
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 Fail 279 (69.1) 
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˥ : 404, ˦ : 403, ˧ : 119, ˨ : 192, ˩ :304, ˪ : 292. 
The relationship between ECOG-PS and measures of body composition and physical function 
are shown in Table 3. ECOG-PS was significantly associated with skeletal muscle index (p < 0.05), 
skeletal muscle radiodensity (p < 0.001) and timed up and go (p < 0.001). 
Table 3. The relationship between Eastern Cooperative Oncology Group-Performance status (ECOG-
PS) and measures of body composition and physical function in patients with advanced cancer (n = 
523). 
High subcutaneous fat index n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p 
No 28 (30.8) 19 (24.7) 7 (29.2) 54 (28.1) 0.677 
Yes 63 (69.2) 58 (75.3) 17 (70.8) 138 (71.9)  
All 91 77 24 192  
High visceral obesity n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p 
No 38 (41.8) 33 (42.9) 8 (33.3) 79 (41.1) 0.700 
Yes 53 (58.2) 44 (57.1) 16 (66.7) 113 (58.9)  
All 91 77 24 192  
Low 54 (28.1)
High 138 (71.9)
Visceral obesity
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% Weight Loss <2.5 292 (56.0) 
 ≥2.5 231 (44.0) 
BMI/WL grade   
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Subcutaneous fat index Low 54 (28.1) 
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Low skeletal muscle index ˩ No 162 (53.3) 
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Low skeletal muscle radiodensity ˪ No 116 (39.7) 
 Yes 176 (60.3) 
˥ : 404, ˦ : 403, ˧ : 119, ˨ : 192, ˩ :304, ˪ : 292. 
The relationship between ECOG-PS and measures of body composition and physical function 
are shown in Table 3. ECOG-PS was significantly associated with skeletal muscle index (p < 0.05), 
skeletal muscle radiodensity (p < 0.001) and timed up and go (p < 0.001). 
Table 3. The relationship between Eastern Cooperative Oncology Group-Performance status (ECOG-
PS) and measures of body composition and physical function in patients with advanced cancer (n = 
523). 
High subcutaneous fat index n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p 
No 28 (30.8) 19 (24.7) 7 (29.2) 54 (28.1) 0.677 
Yes 63 (69.2) 58 (75.3) 17 (70.8) 138 (71.9)  
All 91 77 24 192  
High visceral obesity n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p 
No 38 (41.8) 33 (42.9) 8 (33.3) 79 (41.1) 0.700 
Yes 53 (58.2) 44 (57.1) 16 (66.7) 113 (58.9)  
All 91 77 24 192  
Low 79 (41.1)
High 113 (58.9)
Low skeletal muscle index
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Intermediate Risk 1 91 (17.4) 
High Risk 2 215 (41.1) 
 Body composition  
BMI ≤20.0 kg/m2 74 (14.1) 
 20–21.9 kg/m2 70 (13.4) 
 22–24.9 kg/m2 117 (22.4) 
 25–27.9 kg/m2 107 (20.5) 
 ≥28.0 kg/m2 155 (29.6) 
% Weight Loss <2.5 292 (56.0) 
 ≥2.5 231 (44.0) 
BMI/WL grade   
Low Risk 0/1 276 (52.8) 
Intermediate Risk 2/3 178 (34.0) 
High Risk 4 69 (13.2) 
Subcutaneous fat index Low 54 (28.1) 
 High 138 (71.9) 
Visceral obesity Low 79 (41.1) 
 High 113 (58.9) 
Low skeletal muscle index ˩ No 162 (53.3) 
 Yes 142 (46.7) 
Low skeletal muscle radiodensity ˪ No 116 (39.7) 
 Yes 176 (60.3) 
˥ : 404, ˦ : 403, ˧ : 119, ˨ : 192, ˩ :304, ˪ : 292. 
The relationship between ECOG-PS and measures of body composition and physical function 
are shown in Table 3. ECOG-PS was significantly associated with skeletal muscle index (p < 0.05), 
skeletal muscle radiodensity (p < 0.001) and timed up and go (p < 0.001). 
Table 3. The relationship between Eastern Cooperative Oncology Group-Performance status (ECOG-
PS) and measures of bo y composition and physical function in patients with advanced cancer (n = 
523). 
High subcutaneous fat index n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p 
No 28 (30.8) 19 (24.7) 7 (29.2) 54 (28.1) 0.677 
Yes 63 (69.2) 58 (75.3) 17 (70.8) 138 (71.9)  
All 91 77 24 192  
High visceral obesity n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p 
No 38 (41.8) 33 (42.9) 8 (33.3) 79 (41.1) 0.700 
Yes 53 (58.2) 44 (57.1) 16 (66.7) 113 (58.9)  
All 91 77 24 192  
No 162 (53.3)
Yes 142 (46.7)
Low skeletal muscle radiodensity
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ECOG-PS  
Low Risk 0/1 255 (48.8) 
Intermediate Risk 2 204 (39.0) 
High Risk 3/4 64 (12.2) 
Timed up and go test ˥ Pass 125 (30.9) 
 Fail 279 (69.1) 
Two-minute walk test ˦ Pass 10 (2.5) 
 Fail 393 (97.5) 
Hand grip strength test ˧ Pass  74 (62.2) 
 Fail 45 (37.8) 
 Systemic Inflammation  
mGPS   
Low Risk 0 217 (41.5) 
Intermediate Risk 1 91 (17.4) 
High Risk 2 215 (41.1) 
 Body composition  
BMI ≤20.0 kg/m2 74 (14.1) 
 20–21.9 kg/m2 70 ( 3.4) 
 22–24.9 kg/m  117 (22. ) 
 25–27.9 kg/m2 107 (20.5) 
 ≥28.0 kg/m2 155 (29.6) 
% Weight Loss <2.5 292 (56.0) 
 ≥2.5 231 (44.0) 
BMI/WL grade   
Low Risk 0/1 276 (52.8) 
Intermediate Risk 2/3 178 (34.0) 
High Risk 4 69 (13.2) 
Subcutaneous fat index Low 54 (28.1) 
 High 138 (71.9) 
Visceral obesity Low 79 (41.1) 
 High 113 (58.9) 
Low skeletal muscle index ˩ No 162 (53.3) 
 Yes 142 (46.7) 
Low skeletal muscle radiodensi y ˪ No 116 (39.7) 
 Yes 176 (60.3) 
˥ : 404, ˦ : 403, ˧ : 119, ˨ : 192, ˩ :304, ˪ : 292. 
The relationship b tween ECOG-PS a d measures of body composition and physical function 
are shown in Table 3. ECOG-PS was significantly associated with skeletal muscle index (p < 0.05), 
skeletal muscle radiodensity (p < 0.001) and timed up and go (p < 0.001). 
Table 3. The relationship between Eastern Cooperative Oncology Group-Performance status (ECOG-
PS) and me sures o  body composition and physical function in patients with advanced cancer (n = 
523). 
High subcutaneous fat index n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p 
No 28 (30.8) 19 (24.7) 7 (29.2) 54 (28.1) 0.677 
Yes 63 (69.2) 58 (75.3) 17 (70.8) 138 (71.9)  
All 91 77 24 192  
High visceral obesity n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p 
No 38 (41.8) 33 (42.9) 8 (33.3) 79 (41.1) 0.700 
Yes 53 (58.2) 44 (57.1) 16 (66.7) 113 (58.9)  
All 91 77 24 192  
No 116 (39.7)
Yes 176 (60.3)
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ECOG-PS   
Low Risk 0/1 255 (48.8) 
Interme ate Risk 2 204 (39.0) 
High Risk 3/4 64 (12.2) 
Timed up and go test ˥ Pass 125 (30.9) 
 Fail 279 (69.1) 
Two-minute walk test ˦ Pass 10 (2.5) 
 Fail 393 (97.5) 
Hand grip strength test ˧ Pass  74 (62.2) 
 Fail 45 (37.8) 
 Systemic Inflammation  
mGPS   
Low Risk 0 217 (41.5) 
Intermediate Risk 1 91 (17.4)
High Risk 2 215 (41.1) 
 Body co position  
BMI ≤20.0 kg/m2 74 (14.1) 
 20–21.9 kg/m2 70 (13.4) 
 22–24.9 kg/m2 117 (22.4) 
 25–27.9 kg/m2 107 (20.5) 
 ≥28.0 kg/m2 155 (29.6) 
% Weight Loss <2.5 292 (56.0) 
 ≥2.5 231 (44.0) 
BMI/WL grade   
Low Risk 0/1 276 (52.8) 
Intermediate Risk 2/3 178 (34.0) 
High Risk 4 69 (13.2) 
Subcutaneous fat index Low 54 (28.1) 
 High 138 (71.9) 
Visceral obesity Low 79 (41.1) 
 High 113 (58.9) 
Low skeletal muscle index ˩ No 162 (53.3) 
 Yes 142 (46.7) 
Low skel tal muscle radiodensity ˪ No 116 (39.7) 
 Y s 176 (60.3) 
˥ : 404, ˦ : 403, ˧ : 119, ˨ : 192, ˩ :304, ˪ : 292. 
The relati nship between ECOG-PS and mea ures of body composition and physical function 
are shown in Table 3. ECOG-PS was significantly associated with skeletal muscle index (p < 0.05), 
skeletal muscle radiodensity (p < 0.001) and timed up and go (p < 0.001). 
Table 3. The relationship between Eastern Cooperative Oncology Group-Performance status (ECOG-
PS) and measures of body composition and physical function in patients with advanced cancer (n = 
523). 
High subcutaneous fat index n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p 
No 28 (30.8) 19 (24.7) 7 (29.2) 54 (28.1) 0.677 
Yes 63 (69.2) 58 (75.3) 17 (70.8) 138 (71.9)  
All 91 77 24 192  
High visceral obesity n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p 
No 38 (41.8) 33 (42.9) 8 (33.3) 79 (41.1) 0.700 
Yes 53 (58.2) 44 (57.1) 16 (66.7) 113 (58.9)  
All 91 77 24 192  
: 404,
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ECOG-PS  
Low Risk 0/1 25  (48.8) 
Intermediate Risk 2 204 (39.0) 
High Risk 3/4 64 (12.2) 
Timed up and go test ˥ Pas  125 (30.9) 
 Fail 279 (69.1) 
wo-minute walk test ˦ Pas  10 (2.5) 
 Fail 393 (97.5) 
Hand grip strength test ˧ Pas   74 (62.2) 
 Fail 45 (37.8) 
 Systemic Inflammation  
mGPS   
Low Risk 0 17 (41.5)
Intermediate Risk 1 91 (17.4) 
High Risk 2 215 (41.1) 
 Body co position  
BMI ≤20.0 kg/m2 74 (14.1) 
 20–21.9 kg/m2 70 (13.4) 
 2 –24.9 kg/m2 1 7 (2 .4) 
 25–27.9 kg/m2 107 (20.5) 
 ≥28.0 kg/m2 15  (29.6) 
% Weight Los  <2.5 292 (56.0) 
 ≥2.5 231 (4 .0) 
BMI/WL grade   
Low Risk 0/1 276 (52.8) 
Intermediate Risk 2/3 178 (34.0) 
High Risk 4 69 (13.2) 
Subcutaneous fat index Low 54 (28.1) 
 High 138 (71.9) 
Visceral obesity Low 79 (41.1) 
 High 1 3 (58.9) 
Low skeletal muscle index ˩ No 162 (53.3) 
 Yes 142 (46.7) 
Low skeletal muscle radiodensity ˪ No 1 6 (39.7) 
 Ye  176 (60.3) 
˥ : 40  ˦ : 403, ˧ : 1 9, ˨ : 192, ˩ :304, ˪ : 292. 
The relationship betwe n ECOG-PS a d m asures of body composition and physical function 
a e shown in Table 3. ECOG-PS was significantly as ociated with skeletal muscle index (p < 0.05), 
skeletal muscle radiodensity (p < 0.0 1) and timed up and go (p < 0.0 1). 
Table 3. The relationship betwe n Eastern Co perative Oncology Group-Performance status (ECOG-
PS) and measures of body composition and physical function in patients with advanced cancer (n = 
523). 
High subcutaneous fat index n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p 
No 28 (30.8) 19 (24.7) 7 (29.2) 54 (28.1) 0.67  
Yes 63 (69.2) 58 (75.3) 17 (70.8) 138 (71.9)  
All 91 7  24 192  
High visceral obesity n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p 
No 38 (41.8) 3  (42.9) 8 (3 .3) 79 (41.1) 0.70  
Yes 53 (58.2) 4  (57.1) 16 (6 .7) 1 3 (58.9)  
All 91 7  24 192  
: 403,
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ECOG-PS   
L w Risk 0/1 25  (48. ) 
Intermediate Risk 2 204 (39.0) 
High Risk 3/4 64 (12. ) 
Timed up and go test ˥ Pas  125 (30.9) 
 Fail 279 (69.1) 
Two-minute walk test ˦ Pas  10 (2.5) 
 F il 393 (97.5) 
Hand grip strength test ˧ Pas   74 (62. ) 
 Fail 45 (37.8) 
 Systemic Inflam ation  
mGPS   
Low Risk 0 217 (41.5) 
Intermediate Risk 1 91 (17.4) 
High Risk 2 215 (41. ) 
 Body composition  
BMI ≤20.  kg/m2 74 (14.1) 
 20–21.9 kg/m  70 (13.4) 
 2 –24.9 kg/m2 1 7 (2 .4) 
 25–27.9 kg/m2 107 (20.5) 
 ≥28.0 kg/m2 15  (29.6) 
% Weight Los  <2.5 292 (56.0) 
 ≥2.5 231 (4 .0) 
BM /WL grade   
Low Risk 0/1 276 (52.8) 
Intermediate Risk 2/3 178 (34.0) 
High Risk 4 69 (13.2) 
Subcutaneous fat index Low 54 (28.1) 
 High 138 (71.9) 
Visceral obesity Low 79 (41. ) 
 High 1 3 (58.9) 
Low skel tal muscle index ˩ No 162 (53. ) 
 Yes 142 (46.7) 
Low skel tal mu cle radiodensity ˪ No 1 6 (39.7) 
 Yes 176 (60.3) 
˥ : 40 , ˦ : 4  ˧ : 1 9, ˨ : 192, ˩ :304, ˪ : 29 . 
The relationsh p betwe n ECOG-PS and measures of body composition and physical function 
are shown i  Table 3. ECOG-PS was ignificantly as ociated with skel tal muscle index (p < 0. 5), 
skel tal muscle radiodensity (p < 0. 1) and timed up and go p < 0. 1). 
Table 3. The relationship betwe n Eastern Co perative Oncol gy Group-Performance sta us (ECOG-
PS) and measures of body composition and physical function in patients with advanced cancer (n = 
523). 
High subcutaneous fat index n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 Al  p 
No 28 (30.8) 19 (24.7) 7 (29.2) 54 (28.1) 0.67  
Yes 63 (69.2) 58 (75.3) 17 (70.8) 138 (71.9)  
Al  91 7  24 192  
High visceral obesity n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 Al  p 
No 38 (41.8) 3  (42.9) 8 (3 . ) 79 (41. ) 0.70  
Yes 53 (58.2) 4  (57.1) 16 (6 .7) 1 3 (58.9)  
Al  91 7  24 192  
: 119,
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ECOG-PS   
Low Risk 0/1 25  (48. ) 
Interm diate Risk 2 204 (39.0) 
High Risk 3/4 64 (12. ) 
Timed up and go test ˥ Pas  125 (30.9) 
 Fail 279 (69.1) 
Two-minute walk test ˦ Pas  10 (2.5) 
 Fail 39  97.5) 
Hand grip strength est ˧ Pas   74 (62. ) 
 Fail 45 (37.8) 
 Systemic Inflam ation  
mGPS   
Low Risk 0 217 (41.5) 
Interm diate Risk 1 91 ( 7.4) 
High Risk 2 215 (41. ) 
 Body composition  
BMI ≤20.  kg/m2 74 (14. ) 
 20–21.9 kg/m2 70 (13.4) 
 22– 4.9 kg/m2 117 (22.4) 
 25–27.9 kg/m2 107 (20.5) 
 ≥28.0 kg/m2 15  (29.6) 
% Weight Los  <2.5 29  (56.0) 
 ≥2.5 231 (44.0) 
BMI/WL grade   
Low Risk 0/1 276 (52.8) 
Intermediate Risk 2/3 178 (34.0) 
High Risk 4 69 (13.2) 
Subcutaneous fat index Low 54 (28.1) 
 High 138 (71.9) 
Visceral obesity Low 79 (41. ) 
 High 113 (58.9) 
Low skel tal muscle index ˩ No 162 (53. ) 
 Yes 142 (46.7) 
Low skel tal muscle radi density ˪ No 116 (39.7) 
 Yes 176 ( 0.3) 
˥ : 40 , ˦ : 403, ˧ : 1  ˨ : 192, ˩ :304, ˪ : 292. 
The r lationship betwe n ECOG-PS and measures of body composition and physical function 
ar  shown i Table 3. ECOG-PS was ignificantly as ociated with skel tal muscle index (p < 0. 5), 
skel tal muscle radiodensity (p < 0. 1) and timed up and go (p < 0. 1). 
Table 3. The r lationship betwe n Eastern Co perative Oncol gy Group-Perfo mance sta us (ECOG-
PS) a d measures of body composition a d physical function i  patients with advanced cancer (n =
523). 
High subcutaneous fat index n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 Al  p 
No 28 (30.8) 19 (24.7) 7 (29. ) 54 (28.1) 0.67  
Yes 63 (69.2) 58 (75.3) 17 (70.8) 138 (71.9)  
Al  91 7  24 192  
High visceral obesity n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 Al  p 
No 38 (41.8) 3  (42.9) 8 (3 . ) 79 (41. ) 0.7  
Yes 53 (58.2) 4  (57.1) 16 (6 .7) 1 3 (58.9)  
Al  91 7  24 192  
: 192,
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ECOG-PS   
Low R sk 0/1 25  (48. ) 
Intermedi te Risk 2 204 (39.0) 
High Risk 3/4 64 (12. ) 
Timed up and go test ˥ Pas  125 (30.9) 
 Fail 279 (6 .1) 
Two-minute walk test ˦ Pas  10 (2.5) 
 Fail 39  ( 7.5) 
Hand grip strength est ˧ Pas   74 (62. ) 
 Fail 45 (37.8) 
 Systemic Inflam ation  
mGPS   
Low Risk 0 217 (41.5) 
Intermed ate Risk 1 91 ( 7.4) 
High Risk 2 215 (41. ) 
 Body composit on  
BMI ≤20.  kg/m2 74 (1 . ) 
 20– 1.9 kg/m2 70 (13.4) 
 2 – 4.9 kg/m2 1 7 (2 .4) 
 25– 7.9 kg/m2 107 (20.5) 
 ≥28.0 kg/m2 15  (29.6) 
% Weight Los  <2.5 29  (56.0) 
 ≥2.5 231 (4 .0) 
BMI/WL gra e   
Low Risk 0/1 276 (52.8) 
Intermediate Risk 2/3 178 (34.0) 
High Risk 4 69 (13.2) 
Subc taneous fat index Low 54 (28.1) 
 High 138 (71.9) 
Visceral obesity Low 79 (41. ) 
 High 1 3 (58.9) 
Low skel tal muscle index ˩ No 162 (53. ) 
 Yes 142 ( 6.7) 
L w skel al muscl  radio ns ty ˪ No 1 6 (39.7) 
 Yes 176 ( 0.3) 
˥ : 404, ˦ : 403, ˧ : 1 9, ˨ : 19 ˩ :304, ˪ : 292. 
The r lationship betw n ECOG-PS a d measures of body composit o a d physical function 
are shown i Table 3. ECOG-PS was ign f cantly as ociated with skel ta  muscle index (p < 0. 5), 
skel ta  muscle radio ensity (p < 0. 1  and timed up and go (p < 0. 1). 
Table 3. The r lationship betw n Eastern Co perative Oncol gy Group-Perfo mance sta us (ECOG-
PS) and measures of b dy composition a d physical function patien s with adv nced can er (n =
523). 
High subc taneous fat index n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 Al  p 
No 28 (30.8) 19 (24.7) 7 (29. ) 54 (28.1) 0.67  
Yes 63 ( 9.2) 58 (75.3) 17 ( 0.8) 138 (71.9)  
Al  91 7  24 192  
High visceral obesity n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 Al  p 
No 38 (41.8) 3  (42.9) 8 (3 . ) 79 (41. ) 0.7  
Yes 53 ( 8.2) 4  (57.1) 16 ( .7) 1 3 (58.9)  
Al  91 7  24 192  
: ,
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The relationship between ECOG-PS and measures of body composition and physical function are
shown in Table 3. ECOG-PS was significantly associated with skeletal muscle index (p < 0.05), skeletal
muscle radiodensity (p < 0.001) and timed up and go (p < 0.001).
Table 3. The relationship between Eastern Cooperative Oncology Group-Performance status (ECOG-PS)
and measures of body composition and physical function in patients with advanced cancer (n = 523).
High subcutaneous
fat index n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p
No 28 (30.8) 19 (24.7) 7 (29.2) 54 (28.1) 0.677
Yes 63 (69.2) 58 (75.3) 17 (70.8) 138 (71.9)
All 91 77 24 192
High visceral
obesity n = 192 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p
No 38 (41.8) 33 (42.9) 8 (33.3) 79 (41.1) 0.700
Yes 53 (58.2) 44 (57.1) 16 (66.7) 113 (58.9)
All 91 77 24 192
Low skeletal muscle
index n = 304 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p
No 101 (59.8) 49 (45.8) 12 (42.9) 162 (53.3) 0.039
Yes 68 (40.2) 58 (54.2) 16 (57.1) 142 (46.7)
All 169 107 28 304
Low skeletal muscle
radiodensity n = 292 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p
No 74 (46.5) 40 (38.5) 2 (7.4) 116 (39.7) 0.001
Yes 85 (53.5) 66 (61.5) 25 (92.6) 176 (60.3)
All 159 104 27 292
Timed up and go
test failure n = 404 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p
No 94 (54.3) \ 29 (17.0) 2 (3.3) 125 (30.9) <0.001
Yes 79 (45.7) 142 (83.0) 58 (96.7) 279 (69.1)
All 173 171 60 404
Hand grip strength
test failure n = 119 ECOG-PS 0/1 ECOG-PS 2 ECOG-PS 3/4 All p
No 56 (68.3) 16 (48.5) 2 (50.0) 74 (62.2) 0.123
Yes 26 (31.7) 17 (51.5) 2 (50.0) 45 (37.8)
All 82 33 4 119
The relationship between mGPS and measures of body composition and physical function are
shown in Table 4. mGPS was significantly associated with skeletal muscle radiodensity (p < 0.01),
timed up and go test failure (p ≤ 0.001), and hand grip strength test failure (p < 0.01).
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Table 4. The relationship between modified Glasgow Prognostic Score (mGPS), and measures of body
composition and physical function in patients with advanced cancer (n = 523).
High subcutaneous
fat index n = 192 mGPS = 0 mGPS = 1 mGPS = 2 All p
No 22 (29.3) 5 (16.7) 27 (31.0) 54 (28.1) 0.306
Yes 53 (70.7) 25 (83.3) 60 (69.0) 138 (71.9)
All 75 30 87 192
High visceral
obesity n = 192 mGPS = 0 mGPS = 1 mGPS = 2 All p
No 32 (42.7) 9 (30.0) 38 (43.7) 79 (41.1) 0.398
Yes 43 (57.3) 21 (70.0) 49 (56.3) 113 (58.9)
All 75 30 87 192
Low skeletal muscle
index n = 304 mGPS = 0 mGPS = 1 mGPS = 2 All p
No 72 (55.4) 27 (61.4) 63 (48.5) 162 (53.3) 0.273
Yes 58 (44.6) 17 (38.6) 67 (51.5) 142 (46.7)
All 130 44 130 304
Low skeletal muscle
radiodensity n = 292 mGPS = 0 mGPS = 1 mGPS = 2 All p
No 62 (50.4) 15 (34.1) 39 (31.2) 116 (39.7) 0.006
Yes 61 (49.6) 29 (65.9) 86 (68.8) 176 (60.3)
All 123 44 125 292
Timed up and go
test failure n = 404 mGPS = 0 mGPS = 1 mGPS = 2 All p
No 66 (41.3) 21 (27.6) 38 (22.6) 125 (30.9) 0.001
Yes 94 (58.8) 55 (72.4) 130 (77.4) 279 (69.1)
All 160 76 168 404
Hand grip strength
test failure n = 119 mGPS = 0 mGPS =1 mGPS = 2 All p
No 44 (77.2) 8 (53.3) 22 (46.8) 74 (62.2) 0.005
Yes 13 (22.8) 7 (46.7) 25 (53.2) 45 (37.8)
All 57 15 47 119
The relationship between BMI/WL grade and measures of body composition and physical function
are shown in Table 5. BMI/WL grade was significantly associated with visceral obesity (p < 0.05) and
skeletal muscle radiodensity (p < 0.01).
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Table 5. The relationship between body mass index/weight loss (BMI/WL) grade and measures of body
composition and physical function measurements in patients with advanced cancer (n = 523).
High subcutaneous
fat index n = 192
BMI/WL
grade 0/1
BMI/WL
grade 2/3
BMI/WL
grade 4 All p
No 20 (22.0) 23 (30.7) 11 (42.3) 54 (28.1) 0.104
Yes 71 (78.0) 52 (69.3) 15 (57.7) 138 (71.9)
All 91 75 26 192
High visceral
obesity n = 192
BMI/WL grade
0/1
BMI/WL grade
2/3
BMI/WL grade
4 All p
No 30 (33.0) 33 (44.0) 16 (61.5) 79 (41.1) 0.027
Yes 61 (67.0) 42 (56.0) 10 (38.5) 113 (58.9)
All 91 75 26 192
Low skeletal muscle
index n = 304
BMI/WL grade
0/1
BMI/WL grade
2/3
BMI/WL grade
4 All p
No 93 (57.8) 56 (51.9) 13 (37.1) 162 (53.3) 0.080
Yes 68 (42.2) 52 (48.1) 22 (62.9) 142 (46.7)
All 161 108 35 304
Low skeletal muscle
radiodensity n = 292
BMI/WL grade
0/1
BMI/WL grade
2/3
BMI/WL grade
4 All p
No 70 (45.8) 41 (39.4) 5 (14.3) 116 (39.7) 0.003
Yes 83 (54.2) 63 (60.6) 30 (85.7) 176 (60.3)
All 153 104 35 292
Timed up and go
test failure n = 404
BMI/WL grade
0/1
BMI/WL grade
2/3
BMI/WL grade
4 All p
No 68 (33.7) 41 (28.9) 16 (26.7) 125 (30.9) 0.473
Yes 134 (66.3) 101 (71.1) 44 (73.3) 279 (69.1)
All 202 142 60 404
Hand grip strength
test failure n = 119
BMI/WL grade
0/1
BMI/WL grade
2/3
BMI/WL grade
4 All p
No 47 (63.5) 21 (58.3) 6 (66.7) 74 (62.2) 0.835
Yes 27 (36.5) 15 (41.7) 3 (33.3) 45 (37.8)
All 74 36 9 119
Low skeletal muscle radiodensity was significantly associated with timed up and go test failure
(n = 192, p = 0.015) and hand grip strength failure (n = 100, p = 0.042).
The relationship between ECOG-PS, mGPS, BMI/WL grade, and subcutaneous fat index in patients
with advanced cancer is shown in Table 6. On multivariate binary logistic regression analysis, BMI/WL
grade (OR 0.62, 95%CI 0.40–0.97, p< 0.05) remained independently associated with a high subcutaneous
fat index.
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Table 6. The relationship between ECOG-PS, mGPS, BMI/WL grade and skeletal muscle index, skeletal
muscle radiodensity and physical function in patients with advanced cancer (n = 523).
High subcutaneous fat index Univariate p-value Multivariate p-value
ECOG-PS 1.13 (0.71–1.78) 0.617 – 0.319
mGPS 0.95 (0.67–1.34) 0.776 – 0.995
BMI/WL Grade 0.62 (0.40–0.97) 0.036 0.62 (0.40–0.97) 0.036
High visceral obesity Univariate p-value Multivariate p-value
ECOG-PS 1.12 (0.74–1.70) 0.606 – 0.254
mGPS 0.97 (0.71–1.33) 0.865 – 0.844
BMI/WL Grade 0.57 (0.38–0.87) 0.009 0.57 (0.38–0.87) 0.009
Low skeletal muscle index Univariate p-value Multivariate p-value
ECOG-PS 1.53 (1.08–2.17) 0.016 1.90 (1.51–2.39) <0.001
mGPS 1.15 (0.90–1.47) 0.264 – 0.768
BMI/WL Grade 1.44 (1.03–2.00) 0.033 – 0.106
Low skeletal muscle
radiodensity Univariate p-value Multivariate p-value
ECOG-PS 2.01 (1.36–2.98) <0.001 1.68 (1.11–2.55) 0.013
mGPS 1.50 (1.16–1.95) 0.002 1.32 (1.01–1.73) 0.049
BMI/WL Grade 1.77 (1.23–2.55) 0.002 1.50 (1.02–2.19) 0.037
Timed up and go test failure Univariate p-value Multivariate p-value
ECOG-PS 5.84 (3.79–9.00) <0.001 5.84 (3.79–9.00) <0.001
mGPS 1.56 (1.22–1.98) <0.001 – 0.231
BMI/WL Grade 1.20 (0.89–1.61) 0.232 – 0.484
Hand grip strength test failure Univariate p-value Multivariate p-value
ECOG-PS 1.93 (0.97–3.84) 0.060 – 0.213
mGPS 1.95 (1.29–2.97) 0.002 1.95 (1.29–2.97) 0.002
BMI/WL Grade 1.05 (0.59–1.89) 0.862 – 0.621
The relationship between ECOG-PS, mGPS, BMI/WL grade and high visceral obesity is shown in
Table 6. On multivariate binary logistic regression analysis, BMI/WL grade (OR 0.57, 95%CI 0.38–0.87,
p < 0.01) remained independently associated with a high visceral obesity.
The relationship between ECOG-PS, mGPS, BMI/WL grade and low skeletal muscle index is
shown in Table 6. On multivariate binary logistic regression analysis, ECOG-PS (OR 1.90, 95%CI
1.51–2.39, p < 0.001) remained independently associated with a low skeletal muscle index.
The relationship between ECOG-PS, mGPS, BMI/WL grade and low skeletal muscle radiodensity
is shown in Table 6. On multivariate binary logistic regression analysis, ECOG-PS (OR 1.68, 95%CI
1.11–2.55, p < 0.05), mGPS (OR 1.32, 95%CI 1.01–1.73, p < 0.05) and BMI/WL grade (OR 1.50, 95%CI
1.02–2.19, p < 0.05) remained independently associated with a low skeletal muscle radiodensity.
The relationship between ECOG-PS, mGPS, BMI/WL grade and timed up and go test is shown
in Table 6. On multivariate binary logistic regression analysis, ECOG-PS (OR 5.84, 95%CI 3.79–9.00,
p < 0.001) remained independently associated with timed up and go failure.
The relationship between ECOG-PS, mGPS, BMI/WL grade and hand grip strength is shown in
Table 6. On multivariate binary logistic regression analysis, mGPS (OR 1.95, 95%CI 1.29–2.97, p < 0.01)
remained independently associated with hand grip strength failure.
4. Discussion
Over the last decade or so there has been increasing interest in identifying objective criteria to
define cancer cachexia. This has proven problematic since cancer cachexia is a syndrome impacting
on quality of life, body composition, physical function, and survival. In the present study, candidate
criteria were directly compared in terms of their relationship with measures of body composition and
physical function. ECOG-PS and mGPS were consistently associated with low skeletal muscle mass
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and function and therefore, together with our previous study [11], both ECOG-PS and mGPS would
appear to pass the duck test as criteria to define cancer cachexia.
In the present study, poor performance status was significantly associated with low skeletal
muscle index, low skeletal muscle radiodensity, and timed up and go test failure but not hand grip
strength test failure. Furthermore, high mGPS was significantly associated with low skeletal muscle
radiodensity, timed up and go test failure, and hand grip strength test fail. In contrast, high BMI/WL
grade was significantly associated with high subcutaneous fat index, high visceral obesity, and low
skeletal muscle radiodensity. Therefore, BMI/WL grade appears to capture elements of the decline in
fat mass. The present and previous [11] results clearly need to be repeated to prove the clinical utility
of the ECOG-PS/mGPS framework. However, if this proves to be the case (and these observations are
readily repeated) there are a number of important implications for the future diagnosis and treatment
of cancer cachexia. The present results would suggest that in addition to ECOG-PS, mGPS is useful
in defining the syndrome of cancer cachexia. Therefore, the ECOG/mGPS framework should be
considered as part of routine assessment prior to treatment in patients with advanced cancer.
In the present study it was of interest that low skeletal muscle radiodensity was significantly
associated with timed up and go test failure (p < 0.05) and hand grip strength test failure (p < 0.05).
These results would be consistent with the results of a recent study by Williams and co-workers who
reported that skeletal muscle radiodensity was related to physical function impairments including
activities of daily living (ADL), climbing stairs, walking, and timed up and go [29]. Furthermore, the
presence of systemic inflammatory response degrades the quality of the skeletal muscle [30]. If this
were to be the case then it might be anticipated that downregulation of the systemic inflammatory
response, compared with placebo, would result in better preservation of muscle density, muscle
strength, and performance status. This hypothesis is the subject of a number of ongoing randomised
clinical trials. For example, there is a randomised placebo controlled phase III trial underway of a
multimodal intervention (exercise, nutrition, anti-inflammatory medication) in patients with advanced
lung or pancreatic cancer undergoing anti-cancer therapy with palliative intent (NCT02330926) [31].
The aim of this trial is to prevent or attenuate loss of weight, muscle, and physical function using a
multimodal intervention which is anti-inflammatory. The findings from the associated phase II trial
provide grounds for optimism for the ongoing phase III trial [32].
In the present study, three criteria were considered to define cachexia. With reference to ECOG-PS
this has long been considered a cornerstone of assessment by oncologists and palliative physicians.
With the increasing integration of oncology and palliative care this is likely to remain an important part
of the assessment of the patient with advanced cancer. It may be that other objective measurements
of “real life” performance status will more consistently reflect ECOG-PS, such as activity trackers
(e.g., Fitbit) [33–35]. With reference to the mGPS there has been in recent years extensive validation
of its use in patients with advanced care, and routine assessment is now advocated [36,37]. Of the
present criteria considered, it is the only one that is completely objective as it relies on two routine,
laboratory-derived values. Indeed, it has been termed “laboratory cachexia” as its values become
increasingly abnormal towards death [38] and the mGPS above has been used to define cancer
cachexia [39,40]. There are other measures of the systemic inflammatory response that have been
shown to have prognostic value, such as the neutrophil lymphocyte ratio which can be collected as
part of the routine differential white cell count. However, such ratios have not been well defined
and their relationship with the syndrome of cachexia has not been shown [7,41,42]. With reference
to BMI/WL grade it is not clear whether this has additional value to other nutritional risk screening
tools such as the Malnutrition Universal Screening Tool (MUST) and the Patient Generated Subjective
Global Assessment (PG-SGA) that are in routine clinical use [36,40]. Therefore, further comparative
studies are required to establish the value of BMI/WL grade as a measure of cachexia in patients with
advanced cancer.
The findings of the present study may also help inform regulatory endpoints in the arena of trials
treating cancer cachexia. To date there has been a lack of concordance in regulatory guidance between
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the EMA and FDA regarding endpoints [43] whilst previously agreed endpoints of skeletal muscle
mass and function have not been realized in multiple clinical trials of varying agents [44–47]. It may be
that moderating the systemic inflammatory response in patients with advanced cancer will produce
more reproducible gains.
Limitations of the present study include that body composition measures and physical function
test data were not available in all patients. In the present study the data were analysed according
to clinically relevant criteria (previously reported to be associated with clinical outcomes such as
survival) rather than statistical criteria. Specifically, categorical rather than continuous analysis was
used and since only 10 out of 403 subjects passed the two-minute walk test this was excluded from
further analysis. Furthermore, the cohort was relatively heterogenous with different cancer types and
specific stages of disease. However, when further stratification of the results was carried out for both
lung cancers and gastrointestinal cancers in particular (n ~180 each, Supplementary Tables S1 and
S2), similar results were obtained on univariate and multivariate analysis to that of the combined
cohort, suggesting that the relationships between ECOG-PS, mGPS, BMI/WL grade and skeletal muscle
index, skeletal muscle density and physical function were not specific to cancer type. With reference to
stage of disease, more than 80% of patients had metastatic disease on study entry and therefore the
heterogeneity of this cohort would have been unlikely to confound the present results. Importantly,
the present results are likely to represent the type of patient cohort being treated by both oncologist
and palliative care physicians. Further work is required to define these relationships in specific tumour
types and at specific stages of disease. Furthermore, objective ongoing measurements of physical
function such as the use of Fitbit monitors would be of considerable interest.
5. Conclusions
In summary, a high ECOG-PS and a high mGPS as outlined in the ECOG-PS/mGPS framework
were consistently associated with poorer body composition and physical function in patients with
advanced cancer. The simplicity and clinical utility of this framework mean that it can be readily
incorporated into the routine assessment of patients with advanced cancer.
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